VerorabVax (vero rabies vaccine) / Sanofi - LARVOL DELTA

Immunogenicity and Safety of a Purified Vero Rabies Vaccine (clinicaltrials.gov) - P2; N=320; Active, not recruiting; Sponsor: Sanofi; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Immunology

Immunogenicity and Safety of a Purified Vero Rabies Vaccine (clinicaltrials.gov) - P2; N=320; Recruiting; Sponsor: Sanofi

New P2 trial • Biosimilar • Immunology

Potency test to discriminate between differentially over-inactivated rabies vaccines: Agreement between the NIH assay and a G-protein based ELISA. (PubMed, Biologicals) - "Of note, the experimental error of the ELISA test was well below that of the NIH test. These results increase the prospect that the ELISA test could be considered a suitable candidate for the replacement of the NIH test."

Journal • Preclinical

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (clinicaltrials.gov) - P3; N=504; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Trial completion date: Apr 2020 ➔ Dec 2020; Trial primary completion date: Nov 2019 ➔ Aug 2020

Clinical • Trial completion date • Trial primary completion date

VRV12: Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen in Pediatric and Adult Populations and as Single Booster Dose to a Subset of Adults (clinicaltrials.gov) - P3; N=1010; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Not yet recruiting ➔ Recruiting

Enrollment open

VRV12: Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen in Pediatric and Adult Populations and as Single Booster Dose to a Subset of Adults (clinicaltrials.gov) - P3; N=1010; Not yet recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company

Clinical • New P3 trial

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (clinicaltrials.gov) - P3; N=504; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (clinicaltrials.gov) - P3; N=504; Not yet recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company

Clinical • New P3 trial

"Rabies vaccine shortage forces Kiwi docs onto plan B ^SM @NZDoctor_news https://t.co/qsyOKkPHDF @NZMAchair @RNZCGP @sanofi @GSK @NZBlood" (@NZDoctor_news)

Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years. (clinicaltrialsregister.eu) - P3; N=600; Sponsor: Sanofi Pasteur SA

Clinical • New P3 trial